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Acellular dermal matrix (ADM) has been in clinical use for decades in numerous surgical 
applications. The ability for ADM to promote cellular repopulation, revascularisation and 
tissue regeneration is well documented. Adipose stem cells have the ability to differen-
tiate into mesenchymal tissue types, including bone and cartilage. The aim of this study 
was to investigate the potential interaction between ADM and adipose stem cells in vitro 
using TGFβ3 and BMP6. Human infrapatellar fat pad-derived adipose stem cells (IPFP-
ASC) were cultured with ADM derived from rat dermis in chondrogenic (TGFβ3 and 
BMP6) medium in vitro for 2 and 4 weeks. Histology, qPCR, and immunohistochemistry 
were performed to assess for markers of chondrogenesis (collagen Type II, SOX9 and 
proteoglycans). At 4 weeks, cell-scaffold constructs displayed cellular changes consis-
tent with chondrogenesis, with evidence of stratification of cell layers and development 
of a hyaline-like cartilage layer superficially, which stained positively for collagen Type II 
and proteoglycans. Significant cell–matrix interaction was seen between the cartilage 
layer and the ADM itself with seamless integration between each layer. Real time qPCR 
showed significantly increased COL2A1, SOX9, and ACAN gene expression over 
4 weeks when compared to control. COL1A2 gene expression remained unchanged 
over 4 weeks. We believe that the principles that make ADM versatile and successful 
for tissue regeneration are applicable to cartilage regeneration. This study demonstrates 
in vitro the ability for IPFP-ASCs to undergo chondrogenesis, infiltrate, and interact with 
ADM. These outcomes serve as a platform for in vivo modelling of ADM for cartilage 
repair.
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inTrODUcTiOn
Cartilage lesions are common, reported in over 60% of all arthroscopic procedures, and often 
cause pain and disability for patients (1, 2). Cartilage damage can also predispose to further 
cartilage loss and development of osteoarthritis (3). The compounding issue is that articular car-
tilage has limited capacity for self-regeneration and healing due to its avascular nature. Current 
methods of osteochondral repair such as microfracture, osteochondral grafting, and autologous 
chondrocyte implantation have suboptimal long-term results due to formation of fibrocartilage, 
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along with other complications such as donor-site morbidity 
and hypertrophy (4–8). Tissue engineering approaches, there-
fore, may offer treatment options that can overcome current 
limitations. The optimal combination of cells, scaffold, and 
biochemical factors may eventually result in true cartilage 
regeneration.
Acellular biological scaffolds have been used in many tissue 
engineering applications for regenerative tissue repair. Acellular 
dermal matrix (ADM) is one type of acellular biological scaffold. 
As described by Livesey et al. (9) in a proof-of-principle study in 
minipigs, the porcine allograft ADM was used as a full-thickness 
skin graft in combination with an ultrathin epidermal graft. 
The unique decellularisation/freeze-drying process preserves 
extracellular matrix (ECM) structure without causing an inflam-
matory or tissue rejection response when transplanted (9). The 
transplanted graft shows revascularisation, repopulation by 
host cells, and volume persistence (9). Since this early preclini-
cal study, the human equivalent (AlloDerm®) has been used in 
numerous surgical applications including complex abdominal 
wall hernia repair, full thickness dermal replacement, head and 
neck reconstructive applications, soft-tissue defect augmentation, 
rhinoplasty, alloplastic breast reconstruction, vaginal repair, and 
tendon repair (10).
Adult mesenchymal progenitor cells can be derived from bone 
marrow, fat, skin, muscle, periosteum, or cord blood (11–16). 
Adipose tissue is an attractive source of progenitor cells due to 
ease of accessibility, great abundance, and chondrogenic potential 
(17, 18). While most adipose stromal cells have been extracted 
from liposuction material, a number of studies have utilized adi-
pose stromal cells derived from infrapatellar fat pad (IPFP-ASC) 
(19–23) for the purposes of cartilage repair. Previous research 
has shown that IPFP express superficial zone protein (lubricin), 
which reduces the coefficient of friction at the articular surface 
(21). Recently, we have shown through microarray analysis of 
isolated IPFP-ASCs that a number of chondrogenic genes are 
significantly upregulated when stimulated with the growth fac-
tors TGFβ3 and BMP6 (24). We have also shown the ability for 
these cells to adhere and undergo chondrogenesis on a 3D printed 
chitosan scaffold (25).
Therefore, the aim of this study was to investigate the potential 
interaction between a complete biological scaffold, ADM, and 
stem cells in vitro using our previously reported approach using 
IPFP-ASCs in combination with chondrogenic growth facts, 
TGFβ3 and BMP6 (24, 25).
MaTerials anD MeThODs
ethics approval and Patient selection
Human infrapatellar fat pads were obtained intraoperatively from 
total knee arthroplasties after informed consent and approval 
from Human Research Ethics Committee at St Vincent’s Hospital 
(Melbourne). All necessary ethics protocols were adhered to in 
the process of tissue harvest and use. Only patients with primary 
osteoarthritis were selected. Patients with inflammatory arthritis 
and with a history of prior knee surgery were excluded from 
selection.
cell isolation, culture, and 
characterization
The IPFP were harvested from three individual patients. Each 
IPFP was processed separately and cells from each patient were 
never combined in the in  vitro culture process. The IPFP was 
immediately placed in sterile phosphate buffered saline (PBS) 
(GIBCO, Life Technologies Corporation, Carlsbad, CA, USA) 
and processed within 30 min of harvest. Initially, the tissue was 
washed several times with PBS, to remove contaminating blood. 
The excised fat pad was cleaned from any other adherent tissues 
prior to the cell isolation procedure. The subsequent remaining 
fat tissue was diced and digested with 0.2% Collagenase Type 1 
(Worthington Biochemical Corporation, Lakewood, NJ, USA) 
for 3 h at 37°C under constant agitation. The entire digest was 
filtered through a 100-μm nylon mesh and centrifuged at 400 g 
at room temperature for 5 min to remove adipocytes (floating). 
The cell pellet was resuspended in Red Cell Lysis Buffer (Sigma-
Aldrich, St. Louis, MO, USA) and incubated at room temperature 
for 10 min. The cells were then filtered through a 40-μm nylon 
mesh before centrifugation at 400  g at room temperature for 
5 min. The cells were resuspended in PBS, counted, and plated 
in monolayer culture [75-cm2 tissue culture flask (Corning Inc., 
NY, USA)] at 5 × 103cells/cm2 in stromal media (SM)-containing 
DMEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
10% FBS (GIBCO), 1× antibiotic/antimycotic solution (GIBCO), 
and 1× Glutamax (GIBCO). Cultures were maintained for 48 h 
at 37°C in 5% CO2 in air (Air Liquide Australia Ltd., Melbourne, 
VIC, Australia). The cells were washed and media were replaced 
with expansion media (EM) containing stromal media with 5 ng/
ml human epidermal growth factor (hEGF) (R&D Systems, Inc., 
Minneapolis, MN, USA) and 1 ng/ml human fibroblastic growth 
factor (hFGF) (R&D Systems, Inc.). The cells were cultured until 
80% confluency and then harvested with 0.1% EDTA/0.25% 
trypsin (Sigma-Aldrich) and made into a single cell suspension 
for seeding onto the ADM scaffold (see below).
Cells were characterized, using flow cytometry, and a panel 
of known mesenchymal cell markers, other cell markers, and 
Ig Controls. The methods have been previously published by 
our group (24). Briefly, cells were resuspended in 0.5% bovine 
serum albumin in PBS at a final concentration of 1 × 106 cells/
ml. Cells aliquots (0.25 × 106 cells/200 μl per tube) were stained 
with mesenchymal cell markers (CD29, CD44, CD73, CD90, and 
CD105), as well as other cell markers (CD31, HLADR, CD45) 
(BD Pharmingen) and IgG1 and IgG2a isotype controls (BD 
Pharmingen). All tubes were analyzed within 2 h of staining using 
an FACS Canto flow cytometer system (BD).
scaffold Preparation
Fresh rat skin was harvested from nu/nu rats (Australian Research 
Centre, Perth, WA, Australia). The method of decellularisation 
was slightly modified from the process previously described (9). 
Briefly, fresh tissue was placed immediately in RPMI 1640 medium 
(GIBCO) supplemented with antibiotics, followed by aseptic pro-
cessing (U.S. Patent 5,336,616) performed in a biosafety cabinet. 
This processing involved incubating the skin in high salt solution, 
shaking overnight at room temperature. The epidermis separated 
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from the dermis in this process, dermal cells were removed by 
incubation in non-denaturing detergent, shaking overnight at 
room temperature. The material was cyroprotected in a carbo-
hydrate complex solution. The cyroprotected matrix was packed 
in sterile poly-Tyvek pouches (Beacon Converters Inc., Saddle 
Brook, NJ, USA), heat sealed then freeze-dried (Virtis Genesis 
25L freeze-dryer, SP Industries Warminster, PA, USA). Freeze-
dried tissue was subsequently packed and sealed in foil pouches 
(Beacon Converters Inc.) and stored at −80°C until use. Scaffolds 
were characterized histologically and immunohistochemistry for 
structural integrity and compared to fresh tissue. Matrix samples 
were pre-qualified for biological integrity using a sub-dermal 
implant in immunocompetent rats (not shown).
chondrogenic Differentiation and culture
Confluent passage three IPFP-ASCs were harvested, counted, and 
resuspended in chondrogenic medium (CM) consisting of DMEM-
high glucose, 1% FBS, 1% ITS, 100 nM Dexamethasone, 50 ug/
ml ascorbic acid, 1× antibiotic/antimycotic, 10 ng/ml TGFβ3, and 
10 ng/ml BMP6. Scaffolds were cut using a 6-mm biopsy punch 
(Kai Medical, Honolulu, HI, USA) and placed in a 24-Transwell® 
tissue culture plate well inserts (6.5  mm ID, 3.0 μm pore size) 
(Corning Inc.) and then seeded with 7.5 × 105 ASCs. Cell-ADM 
constructs were incubated at 37°C in 5% CO2 for 14 and 28 days (2 
and 4 weeks) and media changed three times per week. Cell-matrix 
constructs in media without growth factors served as the negative 
control (non-chondrogenic). A total of six scaffolds for the 2- and 
4-week time points for each biological sample (N = 3 IPFP sources; 
n = 36 wells total). These cell-ADM constructs were used for gene 
expression analysis. Two scaffolds cultured for 4 weeks, were used 
for histological and immunohistochemical analysis.
histology and immunohistochemistry
After 4  weeks of culture, cell-ADM constructs were harvested, 
fixed overnight in 10% neutral buffered formalin (NBF) 
(Sigma-Aldrich) and were then paraffin embedded (Pathology 
Department, St Vincent’s Hospital, Melbourne) for subsequent 
histological and immunohistochemical analysis. Samples were 
sectioned (4  μm thick) and dried overnight at 37°C. Sections 
were deparaffinized, rehydrated through graded ethanol, and 
stained with hematoxylin & eosin (H&E) and toluidine blue (TB) 
(Sigma-Aldrich). TB staining was used to stain for proteoglycans 
within the cartilaginous tissue.
Accumulation of collagen Type I and II was assessed by immu-
nohistochemistry. Briefly, sections were treated with 0.3% hydro-
gen peroxide (H2O2) (Merck Millipore, Darmstadt, Germany) 
for 5 min, subjected to Proteinase K for antigen retrieval (Dako, 
Glostrup, Denmark) for 4 min and were blocked using 10% nor-
mal rabbit serum (NRS) (Dako) for 30 min at room temperature. 
These sections were incubated with the following primary anti-
bodies: mouse monoclonal anti-human Type II collagen antibody 
(1:500) (MP Biomedical, Solon, OH, USA), goat polyclonal anti-
human Type I collagen (1:500) (SouthernBiotech, Birmingham, 
AL, USA), and mouse monoclonal anti-human cartilage proteo-
glycan antibody (1:500) (Merck Millipore, Billerica, MA, USA) 
for 60  min at 37°C. Isotype negative controls were used at the 
same concentration as their respective primary antibodies: Goat 
IgG isotype control (SouthernBiotech) and mouse IgG isotype 
control (Invitrogen, Life Technologies Corporation). Secondary 
antibodies used were biotinylated rabbit polyclonal anti-goat and 
rabbit anti-mouse antibodies (Dako). Secondary antibodies were 
applied for 30 min at room temperature followed by horseradish 
peroxidase (HRP)-conjugated streptavidin using the Vectastain 
ABC kit according to the manufacturer’s instructions (Vector 
Laboratories Burlingame, CA, USA). The reaction was developed 
using peroxidase substrate 3,3-diaminobenzidine (DAB) for 
5 min (Dako). Sections were counterstained with hematoxylin, 
dehydrated, cleared, and mounted with Pertex (Histolab Products 
AB, Gothenburg, Sweden). Fresh rat skin and rat ADM were 
stained using the same protocols to serve as controls.
Quantitative real Time Pcr
Two and four week cell-ADM constructs were pulverized in 
liquid nitrogen using a mortar and pestle and then homogenized 
in 1 ml of Trizol solution (Ambion, Life Technologies, Carlsbad, 
CA, USA). Samples were purified using the Trizol method and 
silica membrane-based commercial extraction kit (RNeasy mini 
kit, QIAGEN Pty Ltd., Hilden, Germany) according to the manu-
facturer’s protocol. RNA from pre-differentiated cells (day 0) was 
also extracted. The RNA concentration and purity were measured 
using the Agilent 2100 BioAnalyzer (Agilent Technologies, Santa 
Clara, CA, USA). Complimentary DNA copies were reverse 
transcribed from 200 ng total RNA for all samples using oligo-
dT primers and omniscript reverse transcriptase kit according 
to the recommendations of the manufacturer (Qiagen Pty 
Ltd.). Quantitative PCR (qPCR) was performed using standard 
TaqMan® Probe-Based Gene Expression Analysis protocols using 
commercial available probes for Collagen Types I and II, SOX 
9, and Aggrecan (Invitrogen, Life Technologies Corporation). 
The Taqman primer ID for each gene was as follows: COL1A2 
(Hs00164099_m1), COL2A1 (Hs00264051_m1), SOX9 
(Hs01165814_m1), and ACAN (Hs00153936_m1). GAPDH was 
used as the housekeeping gene for relative quantification of gene 
expression (Hs02758991_g1). Liquid handling was performed 
by the CAS1200 series robot by Corbett Robotics (Corbett Life 
Sciences, Qiagen, Hilden, Germany). Subsequent PCR reaction 
was performed using the Roche Lightcycler 480 (Roche, Basel, 
Switzerland) and preliminary data analysis performed using the 
Lightcycler 480 software version 1.5 (Roche).
Data analysis
All numerical data analysis of relative quantification of qPCR 
results was performed in Microsoft Excel 2010 (Microsoft Corp., 
CA, USA) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, 
CA, USA) using the 2(−ΔCT) method. Means, SD, SEM, and 95% 
confidence limits were calculated for each set of results. Friedman’s 
test was used to assess significance between multiple sets of data.
resUlTs
cells and Material characterization
Infrapatellar fat pad-derived adipose stem cells showed a typical 
spindle-shaped fibroblastic morphology, staining strongly for 
CD29, CD44, CD73, CD90, and CD 105 (MSC markers). Staining 
FigUre 2 | immunohistochemistry of processed rat skin. 
Representative figures of immunohistochemistry of rat ADM shows intact 
bundles of collagen Type I fibers throughout the matrix. Some minor 
proteoglycan staining is evident throughout the ADM. There is no staining for 
collagen Type II. All isotype controls (IgG mouse and goat) were negative. 
Scale bars as indicated. Magnification: 10×.
FigUre 1 | histology of processed rat skin. Representative figures of 
H&E of full thickness rat skin (a) and a preparation of rat acellular dermal 
matrix (ADM) (B). This rat ADM preparation shows the removal of the 
epidermis and lack of cells in the dermal layer. The histoarchitecture of the 
dermis of ADM is comparable to fresh skin. Scale bars as indicated. 
Magnification: 10×.
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for CD31 (endothelial cell marker), HLADR (hematopoietic cell 
marker), and CD 45 (leukocytic cell marker) and the isotype 
controls (IgG1 and IgG2a) were negative, as per our previously 
published data (24).
Hematoxylin & eosin staining of normal rat skin and acellular 
rat dermis shows the absence of the epidermal layer in the rat 
ADM, no cells present and normal histoarchitecture of the col-
lagen fibers within the dermis (Figure 1). Immunohistochemical 
staining for collagen Type I revealed intact bundles of collagen 
Type I fibers throughout the matrix as expected. There is no 
staining for collagen Type II as expected. IgG isotype control 
stains for both mouse and goat serve as negative controls for the 
immunohistochemistry stains (Figure  2). Subdermal implants 
into immunocompetent rats showed engraftment, revasculariza-
tion, repopulation of rat ADM with host cells, and no indication 
of any inflammatory response or fibrous encapsulation of the 
tissue. These results indicated that the rat ADM was processed 
appropriately (results not shown).
histology and immunohistochemistry of 
chondrogenic cultures
Hematoxylin & eosin staining of week 4 in vitro chondrogenic 
cell-ADM constructs, showed a change in the overall shape of the 
construct compared with the control. While the control remained 
flat, the chondrogenic culture had developed a cap of cartilaginous 
tissue, changing the ADM, which was soft and was not tethered 
within the well. There was evidence of stratification of cell layers 
within this in vitro construct, with the development of a hyaline-
like cartilage layer superficially. Cells within the cartilaginous 
cap displayed chondrocytic morphology, namely large, rounded 
cells encapsulated in lacunae. There was also evidence of cellular 
infiltration within the ADM, which did not display chondrocytic 
morphology and remained fibroblastic in their appearance. 
A mixed population of cells was seen within the “ADM-cell inter-
action zone” between the cartilage cap and the ADM, indicating 
significant cell-matrix interaction had occurred.
Toluidine blue staining was positive for proteoglycans especially 
toward the center of the cartilaginous cap compared with the upper, 
superficial layer. There was weaker staining within the “ADM-cell 
interaction zone,” and no staining within the ADM itself. The 
control constructs did not stain for toluidine blue (Figure 3).
Type II collagen was detected in the ECM of the cartilaginous 
cap, surrounding the cartilaginous cells. There was diminished 
Type II collagen detected within the zone of interaction and none 
detected within the ADM. Collagen Type II was not detected in any 
FigUre 3 | histology of cell-aDM constructs. Representative histological figures of H&E and toluidine blue (TB) staining are shown for week 4 chondrogenic 
(a,B) and control (c,D) IPFP-ASCs on ADM. Chondrogenic cell-ADM constructs show cells within the cartilaginous cap displaying chondrocytic morphology and 
strong staining for TB indicative of the presence of proteoglycans (white arrow). There is also cellular infiltration within the ADM. Cells of a mixed morphology can be 
seen within the “ADM-cell interaction zone” (black arrow). No evidence of chondrogenic features could be detected in the control group. Scale bars as indicated. 
Magnification: 10×.
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control samples. Similarly proteoglycan was detected in the ECM 
of the cartilaginous cap with decreased expression in the zone of 
interaction and the ADM. There was weak antibody staining of 
proteoglycans within the control ADM, which prompted questions 
of non-specific binding of the antibody or detection of non-carti-
lage specific proteoglycans within the ADM. Some proteoglycans 
may remain within the ADM even after decellularisation. Some 
collagen Type I was detected within the cartilaginous cap; however, 
greater intensity was seen around the periphery of the construct 
and within the ADM-cell interaction zone, and less so within the 
center of the cartilaginous cap. Collagen Type I was also seen in the 
ADM itself as well as the control construct as expected. All isotype 
control staining was negative (Figure  4). While the “ADM-cell 
interaction zone” layer had minimal staining for collagen Type II 
and proteoglycans, cells continued to be grouped or clustered, with 
collagen fibers of the ADM interspersed more readily within this 
layer, forming what appears to be a transition from a predominantly 
cartilaginous upper zone to the ADM biomaterial below.
gene expression
All mRNA expression of chondrogenic markers (COL2A1, SOX9, 
ACAN) were increased in the chondrogenic constructs from 
week 0 to week 4. There were undetectable levels of COL2A1 
gene expression in the IPFL-ASCs prior to plating. In contrast, 
collagen Type II expression was present at 2 weeks and increased 
significantly by week 4 (p < 0.005, Friedman’s test). The expres-
sion of SOX9 and ACAN increased over the 4 weeks. However, 
only the increase of SOX9 expression from week 0 to week 2 
was statistically significant (p <  0.05, t-test). Collagen Type I 
(COL1A2) gene expression was present in the cells from the outset 
and there was no significant change by week 4 (Figure 5A). After 
4  weeks, COL2A1 expression was undetectable in the control 
group and only low levels of SOX9 were expressed in the control. 
The expression of COL2A1 and ACAN at week 4 was significantly 
greater in the chondrogenic group compared with the control 
group (p < 0.05) (Figure 5B). These results are consistent with 
the development of cartilage-like material in vitro.
DiscUssiOn
The clinical dilemma of cartilage repair after injury remains 
unsolved. The natural course of osteochondral defects toward 
fibrocartilage repair is essentially scar formation of the articular 
surface. The resulting fibrocartilaginous repair consists of pre-
dominantly collagen Type I, does not resemble hyaline cartilage 
in its biochemical and biomechanical properties, and leads to 
early degeneration and potentially early osteoarthritis (5). To 
achieve true regeneration without scar, many researchers have 
looked at acellular biological scaffolds. Decellularised tissues act 
as natural scaffolds comprising of extracellular matrix with vary-
ing degrees of structural collagen and carbohydrate preservation. 
The theory behind this approach is that the residual material 
should provide the perfect natural environment for cellular reat-
tachment, migration, differentiation, and proliferation, to achieve 
regeneration against scar formation (26). Recently decellularised 
biological matrices have been used as a substrate for regenera-
tion of a variety of tissue types including skin, cartilage, bladder, 
spinal cord, and myocardium (27–31). Acellular cartilage matrix 
has been used for treatment of chondral and osteochondral 
defects using various methods of scaffold preparation (32–34). 
A common issue with decellularised cartilage tissue is the loss of 
biomechanical strength (35). However, a report by Kang et al. (36) 
shows, in a rabbit osteochondral model using rabbit adipose tis-
sue (dorsal nuchal) stem cells with cross-linked human acellular 
FigUre 4 | immunohistochemistry of cell-aDM constructs. Representative figures of immunohistochemical staining of week 4 chondrogenic and control 
IPFP-ASCs–ADM constructs for collagen Type II and proteoglycan staining of the cartilaginous cap. There was diminished collagen Type II staining within the zone of 
interaction and no staining within the ADM. Collagen Type I was detected throughout, as well as within the ADM. However, there was weaker collagen Type I staining 
centrally within the cartilaginous cap compared with the periphery and the ADM-cell interaction zone. All isotype control staining were negative. Scale bars as 
indicated. Magnification: 10×.
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cartilage matrix, that the repair tissue was approximately 80% in 
mechanical, GAG, and collagen type II composition compared to 
native cartilage at 6 months. However, integration of the implant 
with the host cartilage continues to be an issue (36).
In previous work, we have reported the potential for IPFP-ASCs 
to undergo chondrogenesis on a 3D printed chitosan scaffold (25). 
The present study further demonstrates the versatility of IPFP-ASCs 
to undergo chondrogenesis on a biologically derived substrate such 
as ADM. However, the IPFP-ASCs were observed to interact differ-
ently with ADM, which is an intact biological matrix. The forma-
tion of what appears to be layers of tissue, each with unique features 
in terms of cellular morphology, extracellular matrix staining, and 
distribution of collagen Types I and II Type is evident. The integra-
tion between these layers is also apparent. These outcomes highlight 
the potential of ADM as a cell-delivery vehicle with the potential 
to promote integration and formation of lamellar structures. The 
cells are able to attach, proliferate and differentiate while interacting 
with the ADM. This may aid cartilage repair in vivo, by acting as 
a substrate that allows both stem cells and host tissue (bone and 
cartilage) to integrate seamlessly and repair the tissue.
Within the cartilaginous layer, further differentiation of 
staining can be seen. Cells on the surface appear to be aligned 
more horizontally, with weaker staining for proteoglycans as 
evidenced by the toluidine blue and greater staining for collagen 
FigUre 5 | Quantitative Pcr results. (a) Real time qPCR data comparing 
changes in mRNA gene expression (relative to GAPDH housekeeping gene) 
in the chondrogenic group showed significant increases in collagen Type II 
and SOX9 gene expression over the 4-week period. Collagen Type I was 
expressed by the cells (day 0), and levels remained unchanged over the 4 
week period. **p < 0.005 Friedman’s test, *p < 0.05 t-test. (B) Real-time 
qPCR data comparing gene expression relative to GAPDH between the 
chondrogenic group and control group at the 4-week time point. Both 
collagen Type II and aggrecan gene expressions were significantly increased 
by week 4 in the chondrogenic group compared to the control group. 
Collagen Type II gene expression was undetectable in the control group at 
week 4. **p < 0.005 Friedman’s test, *p < 0.05 t-test.
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Type I compared with staining in the center of the cartilaginous 
layer. This has similarities with the distribution of collagen Type 
I collagen and proteoglycans within mature hyaline cartilage. The 
significance of this phenomenon is limited in the in vitro setting, 
and further investigation is warranted under in vivo conditions 
such as, seen with mechanical pressure or bioreactors (37).
Since collagen Type II staining in the ADM control tissue is 
absent, all collagen Type II produced can be attributed to the 
differentiation of IPFP-ASCs into a chondrocytic phenotype. 
Histologically, the co-localization of collagen Type II and Type 
I may provide evidence of early developmental progression 
at 4  weeks in  vitro. Collagen Type I is also expressed in early 
chondrogenesis as part of the transformation that occurs from 
mesenchymal cells to chondrocytes, consistent with the pre-natal 
development of the knee joint, which starts with a condensation 
of the mesenchyme between the two long bones prior to the 
distinct development of the articular surfaces of the long bones 
(38). In this study, constructs were maintained for only 4 weeks 
and may indicate the need to extend the time period for further 
clarification of the in  vitro development sequence. Changes to 
the composition and structure of the scaffold over time may also 
impact the production of collagen Type I in the cells. Since this was 
an in vitro study, it is difficult to speculate how much remodeling 
may occur in the in vivo setting and hence, potential progression 
toward a normal hyaline cartilage structure, or complete degrada-
tion of the constructs. Our group is currently working toward a 
full in vivo study to evaluate the ADM-cell cartilage constructs.
Proteoglycan staining in ADM tissue is to be expected. Some 
level of proteoglycans remains even after the decellularisation 
process (39). These proteoglycans may possess functional proper-
ties that promote cell growth regulation, growth factor binding, 
and immunoregulation (40, 41) and have been shown to directly 
interact with growth factors such as TGFβ, TNFα, PDGF, EGFR, 
and ILGFR (42–45). The presence of proteoglycans within the 
ADM may contribute to the cellular infiltration, growth and dif-
ferentiation of IPFP-ASCs in the presence of our chondrogenic 
growth medium (TGFβ3 and BMP6). Pietramaggiori et al. (46) 
showed that AlloDerm (human ADM) was able to bind approxi-
mately 50% of growth factors (TGFβ, PDGF, VEGF, and EGF) 
using platelet-rich plasma (PRP) thereby providing a growth 
factor delivery vehicle in vivo (46).
In conclusion, it is apparent that IPFP-ASCs appear to provide 
an excellent source of cells for chondrogenesis. While human 
ADM has been used extensively in the clinical setting for diverse 
surgical procedures, its use in cartilage repair is novel. We believe 
the principles which make ADM versatile and successful for 
tissue regeneration are applicable to cartilage regeneration. This 
study is the first to demonstrate, in an in vitro setting, the ability 
for IPFP-ASCs to undergo chondrogenesis, infiltrate and interact 
with the ADM material. These outcomes serve as a platform for 
moving to in vivo modeling of ADM for cartilage repair.
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